Table 1 Patient's clinical characteristics
n (%) | |
|---|---|
Age* | 42.1 ± 8.3 |
CD4 lymphocyte count (cells/mm3)** | 544.5 (373.5-759.5) |
CD4 nadir (cells/mm3)** | 184.5 (76-275) |
Undetectable HIV-1 viral load (<50 cop/mL) | 789 (85.6) |
Previous AIDS diagnosis | 241 (26.1) |
Hepatitis C (n = 812) | 369 (45.7) |
Genotype HCV (n = 198) | |
1 | 113 (57.1) |
4 | 47 (23.7) |
3 | 36 (18.2) |
2 | 2 (1.0) |
Hepatitis B (n = 150) | 33 (4.3) |
BMI (Kg/m 2 )* | 23.7 (4.4) |
Current smoker | 505 (54.8) |
Hypertension | 153 (16.6) |
Diabetes | 24 (2.6) |
Way of transmission | |
Sexual | 570 (61.8) |
Injectable drug use | 299 (32.4) |
Blood derivatives | 14 (1.5) |
Vertical transmission | 7 (0.8) |
Unknown | 32 (3.5) |
Previous CV disease | 13 (1.4) |
Familiar history of premature CVD | 46 (5.0) |
10-year CV risk (Framingham)** | 2% (1-4) |
Total cholesterol (mg/dL)* (n = 907) | 194.2 (±45.2) |
HDL cholesterol (mg/dL)* (n = 907) | 54.9 (±16.3) |
CT/HDL ratio* (n = 907) | 3.7 (±1.1) |
LDL cholesterol (mg/dL)* (n = 903) | 111.8 (36.6) |
Triglycerides (mg/dL)** | 116 (85-163) |
Patients with hyperlipidemia § | 480 (52.7) |
Glucose (mg/dL)* | 94.7 (±24.2) |
Creatinine (mg/dL)* | 0.78 (±0.19) |
eGFR (mL/min)* | 90.3 (76.9-107.2) |
Current antiretroviral therapy | |
NRTI + NNRTI (Group 2) | 437 (47.4) |
NRTI + PI (Group 1) | 412 (44.7) |
Only NRTI (Group 3) | 62 (6.7) |
NRTI + PI + NNRTI (Group 4) | 11 (1.2) |
Thymidine NRTI | 180 (19.5) |
Median time on current treatment (months)** | 22 (11-36) |
Accumulated time on ART (months)** | 116 (71-149) |